Spiegelmer Inhibition of MCP-1/CCR2 - Potential as an Adjunct Immunosuppressive Therapy in Transplantation

Scandinavian Journal of Immunology

Volumn 82, Issue 2, 2015, Pages 102-109

  Kalnins, A ^a   Thomas, M N ^a   Andrassy, M ^b   Muller S ^a   Wagner, A ^a   Pratschke, S ^a   Rentsch, M ^a   Klussmann, S ^c   Kauke, T ^a   Angele, M K ^a   Bazhin, A V ^a   Fischereder, M ^a   Werner, J ^a   Guba, M ^a   Andrassy, J ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c NOXXON PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CYCLOSPORIN A; IMMUNOMODULATING AGENT; MNOX E 36; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 1 INHIBITOR; UNCLASSIFIED DRUG; APTAMER; CCL2 PROTEIN, MOUSE; CCR2 PROTEIN, MOUSE; CYCLOSPORIN; IMMUNOSUPPRESSIVE AGENT; NOX-E36 APTAMER;

ACUTE GRAFT REJECTION; ALLOTRANSPLANTATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSPOT ASSAY; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; C57BL MOUSE; DRUG EFFECTS; GRAFT REJECTION; IMMUNOLOGY; PROCEDURES;

ANIMALS; APTAMERS, NUCLEOTIDE; CHEMOKINE CCL2; CYCLOSPORINE; GRAFT REJECTION; GRAFT SURVIVAL; HEART TRANSPLANTATION; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; RECEPTORS, CCR2; TRANSPLANTATION, HOMOLOGOUS;

EID: 84936096742     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12310     Document Type: Article

References (30)

1. Gondos A, Dohler B, Brenner H, Opelz G. Kidney graft survival in Europe and the United States: strikingly different long-term outcomes. Transplantation 2013; 95:267-74.
2. Lamb KE, Lodhi S, Meier-Kriesche HU. Long-term renal allograft survival in the United States: a critical reappraisal. Am J Transplant 2011;11:450-62.
3. Lodhi SA, Lamb KE, Meier-Kriesche HU. Solid organ allograft survival improvement in the United States: the long-term does not mirror the dramatic short-term success. Am J Transplant 2011;11:1226-35.
4. Hertz MI. The Registry of the International Society for Heart and Lung Transplantation-Introduction to the 2012 annual reports: new leadership, same vision. J Heart Lung Transplant 2012;31:1045-51.
5. Hancock WW. Chemokine receptor-dependent alloresponses. Immunol Rev 2003;196:37-50.
6. Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R. The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev 2010;21:27-39.
7. Fuentes ME, Durham SK, Swerdel MR et al. Controlled recruitment of monocytes and macrophages to specific organs through transgenic expression of monocyte chemoattractant protein-1. J Immunol 1995;155:5769-76.
8. Carr MW, Roth SJ, Luther E, Rose SS, Springer TA. Monocyte chemoattractant protein 1 acts as a T-lymphocyte chemoattractant. Proc Natl Acad Sci USA 1994;91:3652-6.
9. Charo IF, Myers SJ, Herman A, Franci C, Connolly AJ, Coughlin SR. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. Proc Natl Acad Sci USA 1994;91:2752-6.
10. Sallusto F, Mackay CR, Lanzavecchia A. The role of chemokine receptors in primary, effector, and memory immune responses. Annu Rev Immunol 2000;18:593-620.
11. Klussmann S, Nolte A, Bald R, Erdmann VA, Furste JP. Mirror-image RNA that binds D-adenosine. Nat Biotechnol 1996;14:1112-5.
12. Kulkarni O, Pawar RD, Purschke W et al. Spiegelmer inhibition of CCL2/MCP-1 ameliorates lupus nephritis in MRL-(Fas)lpr mice. J Am Soc Nephrol 2007;18:2350-8.
13. Corry RJ, Winn HJ, Russell PS. Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation 1973;16:343-50.
14. Hoffmann S, Hoos J, Klussmann S, Vonhoff S. RNA aptamers and spiegelmers: synthesis, purification, and post-synthetic PEG conjugation. Curr Protoc Nucleic Acid Chem 2011;Chapter 4:Unit 4 46 1-30.
15. Billingham ME, Cary NR, Hammond ME et al. A working formulation for the standardization of nomenclature in the diagnosis of heart and lung rejection: Heart Rejection Study Group. The International Society for Heart Transplantation. J Heart Transplant 1990;9:587-93.
16. Stojanovic T, Wagner AH, Wang S et al. STAT-1 decoy oligodeoxynucleotide inhibition of acute rejection in mouse heart transplants. Basic Res Cardiol 2009;104:719-29.
17. Johnston DR, Sayegh MH, Madsen JC. Overcoming cardiac allograft vasculopathy (CAV) by inducing tolerance. Front Biosci 2002;7:e116-8.
18. Hancock WW, Wang L, Ye Q, Han R, Lee I. Chemokines and their receptors as markers of allograft rejection and targets for immunosuppression. Curr Opin Immunol 2003;15:479-86.
19. Ninichuk V, Clauss S, Kulkarni O et al. Late onset of Ccl2 blockade with the Spiegelmer mNOX-E36-3'PEG prevents glomerulosclerosis and improves glomerular filtration rate in db/db mice. Am J Pathol 2008;172:628-37.
20. Furness PN, Taub N, Assmann KJ et al. International variation in histologic grading is large, and persistent feedback does not improve reproducibility. Am J Surg Pathol 2003;27:805-10.
21. Mengel M, Sis B, Kim D et al. The molecular phenotype of heart transplant biopsies: relationship to histopathological and clinical variables. Am J Transplant 2010;10:2105-15.
22. Mengel M, Campbell P, Gebel H et al. Precision diagnostics in transplantation: from bench to bedside. Am J Transplant 2013;13:562-8.
23. Gao W, Faia KL, Csizmadia V et al. Beneficial effects of targeting CCR5 in allograft recipients. Transplantation 2001;72:1199-205.
24. Gao W, Topham PS, King JA et al. Targeting of the chemokine receptor CCR1 suppresses development of acute and chronic cardiac allograft rejection. J Clin Invest 2000;105:35-44.
25. Horiguchi K, Kitagawa-Sakakida S, Sawa Y et al. Selective chemokine and receptor gene expressions in allografts that develop transplant vasculopathy. J Heart Lung Transplant 2002;21:1090-100.
26. Belperio JA, Keane MP, Burdick MD et al. Critical role for the chemokine MCP-1/CCR2 in the pathogenesis of bronchiolitis obliterans syndrome. J Clin Invest 2001;108:547-56.
27. Abdi R, Means TK, Ito T et al. Differential role of CCR2 in islet and heart allograft rejection: tissue specificity of chemokine/chemokine receptor function in vivo. J Immunol 2004;172:767-75.
28. Lee I, Wang L, Wells AD et al. Blocking the monocyte chemoattractant protein-1/CCR2 chemokine pathway induces permanent survival of islet allografts through a programmed death-1 ligand-1-dependent mechanism. J Immunol 2003;171:6929-35.
29. Horuk R. Chemokine receptor antagonists: overcoming developmental hurdles. Nat Rev Drug Discovery 2009;8:23-33.
30. Leuschner F, Dutta P, Gorbatov R et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat Biotechnol 2011;29:1005-10.